<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2037">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05134649</url>
  </required_header>
  <id_info>
    <org_study_id>M21-323</org_study_id>
    <nct_id>NCT05134649</nct_id>
  </id_info>
  <brief_title>A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence</brief_title>
  <official_title>Phase 3, Multicenter Open-label Extension Study to Evaluate the Safety of BOTOX (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Platysma Prominence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 3, open-label study to evaluate the safety of BOTOX Injection in Adult&#xD;
      Participants with Platysma Prominence&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Anticipated">November 15, 2021</start_date>
  <completion_date type="Anticipated">June 20, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 20, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>Day 1 to Day 240</time_frame>
    <description>An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a casual relationship with this treatment. The investigator assesses the relationship of each event to the use of the study. A serious adverse event (SAE) is an event that results in death, is life threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event, that based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/ treatment emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first dose of the study drug.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">270</enrollment>
  <condition>Platysma Prominence</condition>
  <arm_group>
    <arm_group_label>BOTOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BOTOX will be injected into the platysma muscle for up to 3 administrations.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BOTOX</intervention_name>
    <description>Intramuscular Injection</description>
    <arm_group_label>BOTOX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Completion of all phases of the lead-in Phase 3 study (Screening Period, Treatment Period&#xD;
        [randomization/treatment with 4-month follow-up visit] and Study Exit visit)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any medical condition that may put the participant at increased medical risk with&#xD;
             exposure to BOTOX, including diagnosed myasthenia gravis, Eaton-Lambert syndrome,&#xD;
             amyotrophic lateral sclerosis, or any other condition that might interfere with&#xD;
             neuromuscular function&#xD;
&#xD;
          -  Participant has an anticipated need for treatment with botulinum toxin of any serotype&#xD;
             for any indication during the study (other than study intervention)&#xD;
&#xD;
          -  Anticipated need for surgery or overnight hospitalization during the study&#xD;
&#xD;
          -  Females who are pregnant or breastfeeding and are considering becoming pregnant or&#xD;
             donating eggs during the study&#xD;
&#xD;
          -  Known immunization or hypersensitivity to any botulinum toxin serotype&#xD;
&#xD;
          -  History of clinically significant (per investigator's judgment) drug or alcohol abuse&#xD;
             within the last 6 months&#xD;
&#xD;
          -  Lower facial and neck hair, scarring (e.g., acne), or other abnormal variations that&#xD;
             may interfere with photography (such that photograph is not acceptable)&#xD;
&#xD;
          -  Tattoos, jewelry, or clothing that cannot be removed, and that obscure the target area&#xD;
             of interest&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ALLERGAN INC.</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Advanced Research Associates - Glendale /ID# 231997</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clear Dermatology &amp; Aesthetics Center /ID# 231990</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85255-4134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Testing of Beverly Hills /ID# 231986</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91436-2124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Research Associates /ID# 231976</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Steve Yoelin MD Medical Assoc. Inc /ID# 232004</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663-3311</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cosmetic Laser Dermatology /ID# 232414</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92121-2119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ava T. Shamban MD - Santa Monica. /ID# 232000</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404-2208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Art of Skin MD /ID# 231995</name>
      <address>
        <city>Solana Beach</city>
        <state>California</state>
        <zip>92075-2228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DMR Research PLLC /ID# 231998</name>
      <address>
        <city>Westport</city>
        <state>Connecticut</state>
        <zip>06880-5369</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Susan H. Weinkle, MD /ID# 232001</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34209-5642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Institute of the Southeast, LLC /ID# 231974</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401-2712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laser and Skin Surgery Center of Indiana /ID# 231983</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260-2386</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coleman Center For Cosmetic Dermatologic Surgery /ID# 231977</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Delricht Research /ID# 231985</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aesthetic Center at Woodholme /ID# 231996</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21208-6391</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maryland Dermatology Laser, Skin, &amp; Vein Institute /ID# 232002</name>
      <address>
        <city>Hunt Valley</city>
        <state>Maryland</state>
        <zip>21030-3216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Image Dermatology, P.C. /ID# 231980</name>
      <address>
        <city>Montclair</city>
        <state>New Jersey</state>
        <zip>07042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laser &amp; Skin Surgery Center of New York /ID# 231982</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016-4974</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aesthetic Solutions /ID# 231978</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27517-9901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilmington Dermatology Center /ID# 231981</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aventiv Research Dublin /ID# 231994</name>
      <address>
        <city>Dublin</city>
        <state>Ohio</state>
        <zip>43016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KGL Skin Study Center, LLC /ID# 231993</name>
      <address>
        <city>Newtown Square</city>
        <state>Pennsylvania</state>
        <zip>19073-2228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nashville Center for Laser and Facial Surgery /ID# 231975</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203-1513</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dallas Plastic Surgery Institute /ID# 231999</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SkinDC /ID# 231989</name>
      <address>
        <city>Arlington</city>
        <state>Virginia</state>
        <zip>22209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Clinical Research /ID# 232003</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Shannon Humphrey Inc. /ID# 239649</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermetics Cosmetic Dermatology /ID# 239650</name>
      <address>
        <city>Burlington</city>
        <state>Ontario</state>
        <zip>L7N 3N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Melinda Gooderham Medicine Profession /ID# 239647</name>
      <address>
        <city>Cobourg</city>
        <state>Ontario</state>
        <zip>K9A 0Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center For Dermatology /ID# 239651</name>
      <address>
        <city>Richmond Hill</city>
        <state>Ontario</state>
        <zip>L4B 1A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.rxabbvie.com/</url>
    <description>This clinical study may be evaluating a usage that is not currently FDA approved. Please see US Prescribing Information for approved uses.</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 15, 2021</study_first_submitted>
  <study_first_submitted_qc>November 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Platysma Prominence</keyword>
  <keyword>BOTOX</keyword>
  <keyword>OnabotulinumtoxinA</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>For details on when studies are available for sharing, please refer to the link below.</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/abbvie/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

